search
Back to results

Stem Cells Treatment for Extremely Complex Fistulae (HULPCIR)

Primary Purpose

Extremely Complex Perianal Fistulae

Status
Unknown status
Phase
Phase 2
Locations
Spain
Study Type
Interventional
Intervention
Adipose-derived stem cells without expanded
Sponsored by
Instituto de Investigación Hospital Universitario La Paz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Extremely Complex Perianal Fistulae focused on measuring Extremely complex perianal fistula, Adipose Derived Stem Cells

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed informed consent
  • Extremely Complex perianal fistulae
  • Men and women over 18 years old. Good general state of health according to the findings of the clinical history and the physical examination
  • Previous failure in at least one closing fistula standard treatment

Exclusion Criteria:

  • Presence of severe proctitis or dominant active luminal disease requiring immediate therapy
  • Patients with an abscess unless a complete toilet of the area with drainage of the collections and the absence of abscess and other collections is confirmed prior to treatment start
  • Patients with a history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion
  • Patients with malignant tumor, except for basal cell or cutaneous squamous cell carcinoma, or patients with a prior history of malignant tumors, unless the neoplastic disease has been in remission for the previous 5 years
  • Patients with cardiopulmonary disease which, in opinion of the investigator, in unstable or sufficiently serious to exclude the patient from the study.
  • Patients with any type of medical or psychiatric disease which, in the opinion of the investigator, could be grounds for exclusion from study
  • Patients with congenital or acquired immunodeficiencies. HIV, HBV, HCV or treponema infection, whether active or latent
  • Patients who have suffering major surgery or severe trauma in the prior 6 months
  • Pregnant or breastfeeding women
  • Patients currently receiving, or having received within 1 month prior to enrollment into this clinical trial, any investigational drug

Sites / Locations

  • Hospital Universitario La PazRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Autologous Stem Cells

Arm Description

Outcomes

Primary Outcome Measures

Safety of treatment of extremely complex perianal fistulae. Percentage of treated extremely complex perianal fistulae and percentage of subjects with closed fistulae
Safety by control the adverse effects associated with treatment Fistula close by 3D ultrasound

Secondary Outcome Measures

Quality of life assessment using the SF-12 Questionnaire
Test SF-12 of quality of life
Adverse events
Control by investigation team of CRD (data collections)

Full Information

First Posted
April 23, 2012
Last Updated
April 25, 2012
Sponsor
Instituto de Investigación Hospital Universitario La Paz
search

1. Study Identification

Unique Protocol Identification Number
NCT01586715
Brief Title
Stem Cells Treatment for Extremely Complex Fistulae (HULPCIR)
Official Title
A Phase IIa Clinical Trial to Study the Treatment of the Extremely Complex and Conventional Treatment Resistant Perianal Fistulae With Autologous Stem Cells From Lipoaspirate
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Unknown status
Study Start Date
March 2012 (undefined)
Primary Completion Date
May 2013 (Anticipated)
Study Completion Date
December 2013 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Instituto de Investigación Hospital Universitario La Paz

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the practicability of the autologous e-ASC (Autologous Stem Cells) for the treatment of extremely complex and treatment resistant perianal fistulae.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Extremely Complex Perianal Fistulae
Keywords
Extremely complex perianal fistula, Adipose Derived Stem Cells

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Autologous Stem Cells
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Adipose-derived stem cells without expanded
Intervention Description
Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Primary Outcome Measure Information:
Title
Safety of treatment of extremely complex perianal fistulae. Percentage of treated extremely complex perianal fistulae and percentage of subjects with closed fistulae
Description
Safety by control the adverse effects associated with treatment Fistula close by 3D ultrasound
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Quality of life assessment using the SF-12 Questionnaire
Description
Test SF-12 of quality of life
Time Frame
1, 4, 16,24 weeks
Title
Adverse events
Description
Control by investigation team of CRD (data collections)
Time Frame
1, 4, 12, 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent Extremely Complex perianal fistulae Men and women over 18 years old. Good general state of health according to the findings of the clinical history and the physical examination Previous failure in at least one closing fistula standard treatment Exclusion Criteria: Presence of severe proctitis or dominant active luminal disease requiring immediate therapy Patients with an abscess unless a complete toilet of the area with drainage of the collections and the absence of abscess and other collections is confirmed prior to treatment start Patients with a history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion Patients with malignant tumor, except for basal cell or cutaneous squamous cell carcinoma, or patients with a prior history of malignant tumors, unless the neoplastic disease has been in remission for the previous 5 years Patients with cardiopulmonary disease which, in opinion of the investigator, in unstable or sufficiently serious to exclude the patient from the study. Patients with any type of medical or psychiatric disease which, in the opinion of the investigator, could be grounds for exclusion from study Patients with congenital or acquired immunodeficiencies. HIV, HBV, HCV or treponema infection, whether active or latent Patients who have suffering major surgery or severe trauma in the prior 6 months Pregnant or breastfeeding women Patients currently receiving, or having received within 1 month prior to enrollment into this clinical trial, any investigational drug
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Damián García Olmo, Prof MD
Phone
0034 912071022
Email
damian.garcia@uam.es
First Name & Middle Initial & Last Name or Official Title & Degree
Mariano A García Arranz, PhD
Phone
0034 912071022
Email
mgarciaa.hulp@salud.madrid.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Damián García Olmo, Prof MD
Organizational Affiliation
General Surgery Department (Hospital Universitario La Paz) and Cell Therapy laboratory
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitario La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariano A García Arranz, PhD
Phone
0034 912071022
Email
mgarciaa.hulp@salud.madrid.org
First Name & Middle Initial & Last Name & Degree
Damián García Olmo, Prof MD
First Name & Middle Initial & Last Name & Degree
Héctor Guadalajara Labajo, MD
First Name & Middle Initial & Last Name & Degree
Tihomir G Hirstov, MD

12. IPD Sharing Statement

Citations:
Citation
Bey NM. A new technique in dealing with superior rectovaginal fistulae. J. Obstrt Gynecol 1934. 41: 579-587
Results Reference
background
PubMed Identifier
4916866
Citation
Given FT Jr. Rectovaginal fistula. A review of 20 years' experience in a community hospital. Am J Obstet Gynecol. 1970 Sep 1;108(1):41-6. No abstract available.
Results Reference
background
Citation
Daniels BT. Rectovaginal fistula: a clinical and pathological study. Doctoral dissertation. Minneapolis: University of Minnesota 1949
Results Reference
background
PubMed Identifier
18895064
Citation
LAIRD DR. Procedures used in treatment of complicated fistulas. Am J Surg. 1948 Dec;76(6):701-8. doi: 10.1016/s0002-9610(48)90211-6. No abstract available.
Results Reference
background
PubMed Identifier
4017820
Citation
Hoexter B, Labow SB, Moseson MD. Transanal rectovaginal fistula repair. Dis Colon Rectum. 1985 Aug;28(8):572-5. doi: 10.1007/BF02554145.
Results Reference
background
PubMed Identifier
2909131
Citation
Fry RD, Shemesh EI, Kodner IJ, Timmcke A. Techniques and results in the management of anal and perianal Crohn's disease. Surg Gynecol Obstet. 1989 Jan;168(1):42-8.
Results Reference
background
PubMed Identifier
3338350
Citation
Radcliffe AG, Ritchie JK, Hawley PR, Lennard-Jones JE, Northover JM. Anovaginal and rectovaginal fistulas in Crohn's disease. Dis Colon Rectum. 1988 Feb;31(2):94-9. doi: 10.1007/BF02562636.
Results Reference
background
PubMed Identifier
421652
Citation
Tuxen PA, Castro AF. Rectovaginal fistula in Crohn's disease. Dis Colon Rectum. 1979 Jan-Feb;22(1):58-62. doi: 10.1007/BF02586761. No abstract available.
Results Reference
background
PubMed Identifier
7429313
Citation
Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980 Jun;21(6):525-7. doi: 10.1136/gut.21.6.525.
Results Reference
background
PubMed Identifier
6624806
Citation
Bandy LC, Addison A, Parker RT. Surgical management of rectovaginal fistulas in Crohn's disease. Am J Obstet Gynecol. 1983 Oct 15;147(4):359-63. doi: 10.1016/s0002-9378(16)32225-6.
Results Reference
background
PubMed Identifier
1992942
Citation
Bauer JJ, Sher ME, Jaffin H, Present D, Gelerent I. Transvaginal approach for repair of rectovaginal fistulae complicating Crohn's disease. Ann Surg. 1991 Feb;213(2):151-8. doi: 10.1097/00000658-199102000-00010.
Results Reference
background
PubMed Identifier
9749498
Citation
Tsang CB, Madoff RD, Wong WD, Rothenberger DA, Finne CO, Singer D, Lowry AC. Anal sphincter integrity and function influences outcome in rectovaginal fistula repair. Dis Colon Rectum. 1998 Sep;41(9):1141-6. doi: 10.1007/BF02239436.
Results Reference
background
PubMed Identifier
17846837
Citation
Andreani SM, Dang HH, Grondona P, Khan AZ, Edwards DP. Rectovaginal fistula in Crohn's disease. Dis Colon Rectum. 2007 Dec;50(12):2215-22. doi: 10.1007/s10350-007-9057-7. Epub 2007 Sep 11.
Results Reference
background
Citation
García Olmo D, García-Verdugo JM, Alemany J, Gonzalez M, Gutierrez-Fuentes JA. CELL THERAPHY . Ed. Mac Graw Hill. Madrid 2007
Results Reference
background
PubMed Identifier
15494428
Citation
Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005 Feb 15;105(4):1815-22. doi: 10.1182/blood-2004-04-1559. Epub 2004 Oct 19.
Results Reference
background
PubMed Identifier
15801964
Citation
Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, Taureau C, Cousin B, Abbal M, Laharrague P, Penicaud L, Casteilla L, Blancher A. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol. 2005 Apr;129(1):118-29. doi: 10.1111/j.1365-2141.2005.05409.x.
Results Reference
background
PubMed Identifier
12589164
Citation
Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003 Feb 15;75(3):389-97. doi: 10.1097/01.TP.0000045055.63901.A9.
Results Reference
background
PubMed Identifier
17656645
Citation
Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007 Nov;25(11):2739-49. doi: 10.1634/stemcells.2007-0197. Epub 2007 Jul 26.
Results Reference
background
PubMed Identifier
15846285
Citation
Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 May;11(5):321-34. doi: 10.1016/j.bbmt.2005.01.005.
Results Reference
background
PubMed Identifier
15820948
Citation
Maccario R, Podesta M, Moretta A, Cometa A, Comoli P, Montagna D, Daudt L, Ibatici A, Piaggio G, Pozzi S, Frassoni F, Locatelli F. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005 Apr;90(4):516-25.
Results Reference
background
PubMed Identifier
14633790
Citation
Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, Cullup H, Jarvis M, Middleton PG, Chao N. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program. 2003:350-71. doi: 10.1182/asheducation-2003.1.350.
Results Reference
background
PubMed Identifier
12756590
Citation
Garcia-Olmo D, Garcia-Arranz M, Garcia LG, Cuellar ES, Blanco IF, Prianes LA, Montes JA, Pinto FL, Marcos DH, Garcia-Sancho L. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis. 2003 Sep;18(5):451-4. doi: 10.1007/s00384-003-0490-3. Epub 2003 May 20.
Results Reference
background
PubMed Identifier
15933795
Citation
Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005 Jul;48(7):1416-23. doi: 10.1007/s10350-005-0052-6.
Results Reference
background
PubMed Identifier
19273960
Citation
Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009 Jan;52(1):79-86. doi: 10.1007/DCR.0b013e3181973487.
Results Reference
background

Learn more about this trial

Stem Cells Treatment for Extremely Complex Fistulae (HULPCIR)

We'll reach out to this number within 24 hrs